Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those ...

The Dividend Harvesting Portfolio hit new all-time highs, delivering a 29.44% return. Learn more about the portfolio and why ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Shares of Pfizer Inc. PFE rallied 3.63% to $25.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...